But even if the antibodies can reduce the number of plaques in the brains of mice, scientists are uncertain how this will affect the manifestations of Alzheimer's disease in humans, like memory loss. Research in mice has studied the vaccine's effects on memory loss in Alzheimer's disease. In December 2000, two independent research teams reported that genetically altered mice that had developed memory deficits improved after repeated vaccinations. The mice took part in tests where they swam until they learned the location of an underwater platform. Not only did vaccinated mice perform better on these memory tests than their untreated counterparts, many also did as well or nearly as well as ordinary mice that were not programmed to develop plaques.
Studies are now underway to test the vaccine on humans.
AN-1792 is still in the first phase of clinical trials . D.C. About 100 people from the United States and England are involved in the first phase of research. Participants in the United States have received a single injection of AN-1792. Cautions It is important to realize that AN-1792 is still in the very early stages of research. Because early-stage research on treatment and prevention measures for Alzheimer's disease is often heavily covered in the media, many families find they need to restrain their optimism when reacting to news reports.